Myasthenia Gravis: How Antibodies Jam the Muscle's Signal

The normal junction: how one nerve impulse fires a muscle

To understand MG you first have to appreciate how reliable the healthy neuromuscular junction is. When an action potential reaches the motor nerve terminal, voltage-gated Ca²⁺ channels open and trigger release of ∼50–300 packets (quanta) of the neurotransmitter acetylcholine (ACh). ACh diffuses across the ∼50 nm cleft and binds nicotinic ACh receptors clustered densely on the crests of the deeply folded postsynaptic membrane. Each receptor is a ligand-gated cation channel; opening lets Na⁺ in, depolarizing the muscle to produce an endplate potential.

The crucial concept is the safety factor: a healthy junction releases far more ACh, and packs far more receptors, than the bare minimum needed to reach threshold. The endplate potential normally overshoots threshold by a wide margin, so essentially every nerve impulse produces a muscle fiber twitch — even though ACh output naturally declines during sustained firing (physiological rundown). This built-in reserve is why you can hold your gaze steady or grip an object without visible fatigue. MG is fundamentally a disease that erodes this safety factor.

What goes wrong: antibodies dismantle the receptor

MG is an antibody-mediated autoimmune disease. In roughly 85% of generalized cases the culprit is IgG1/IgG3 antibodies against the acetylcholine receptor (AChR). They damage the endplate by three cooperating mechanisms:

1. Complement-mediated destruction. Bound IgG activates the complement cascade, forming the membrane-attack complex (C5b-9) that literally erodes and flattens the postsynaptic folds — the single most important lesion, reducing both receptor number and endplate architecture.
2. Antigenic modulation. Antibodies cross-link adjacent receptors, accelerating their internalization and degradation so receptors turn over faster than they can be replaced.
3. Direct functional block. A minority of antibodies sit on the ACh-binding site itself and block the neurotransmitter.

The net result: fewer functional receptors on a simplified, shallow-folded endplate. Now the endplate potential barely clears threshold — the safety factor is gone. At rest, enough transmission remains for normal strength. But as the same fibers fire repeatedly, normal physiological rundown of ACh release drops the already-marginal endplate potential below threshold in more and more fibers. Each failed junction is one fiber that stops contracting — and clinically that is fatigable weakness.

Antibody subtypes and the thymus connection

MG is not one disease but a family defined by antibody target:

• AChR-positive (∼80–85%): the classic form, most strongly linked to thymic pathology.
• MuSK-positive (∼5–8%): antibodies against muscle-specific kinase, which normally clusters AChRs. These patients are more often women with prominent bulbar, facial, neck and respiratory weakness, and they respond poorly — even paradoxically — to cholinesterase inhibitors.
• LRP4-positive and "seronegative": a smaller remainder; some seronegative patients have low-affinity AChR antibodies missed by standard assays.

The thymus is central. About 10–15% of AChR-positive patients harbor a thymoma, and up to ∼60–70% show thymic hyperplasia with germinal centers. The thymus in MG contains myoid cells expressing AChR alongside antigen-presenting and T cells — an ideal breeding ground for autoreactive B cells. This is why chest imaging (CT/MRI) is mandatory at diagnosis and why thymectomy is therapeutic in selected patients.

Classic presentation: fatigable, fluctuating, and ocular-first

Two features together are nearly pathognomonic: weakness that is fatigable (worsens with sustained or repeated effort) and fluctuating (better in the morning and after rest, worse in the evening). Importantly, MG affects the muscle only — there is no numbness, no pain, and reflexes and sensation are normal.

Over half of patients present with ocular symptoms: asymmetric ptosis (drooping eyelid) and binocular diplopia (double vision) from weak extraocular muscles. A classic bedside sign is worsening ptosis on sustained upgaze, and the Cogan lid-twitch sign — a brief overshoot of the upper lid when the eyes flick back to primary gaze from downgaze. Applying ice to a ptotic lid for ∼2 minutes improves it (the ice-pack test), because cooling slows acetylcholinesterase and improves transmission.

As disease generalizes it produces bulbar weakness — nasal/slurred speech that fades mid-sentence, difficulty chewing (jaw fatigue), dysphagia and nasal regurgitation — and proximal, symmetric limb weakness. About 15% of patients stay purely ocular; of those who generalize, most do so within the first 1–2 years.

How it is diagnosed

Diagnosis rests on a compatible clinical picture plus objective confirmation:

• Serology (first-line): serum anti-AChR binding antibodies are ∼85% sensitive in generalized MG (lower, ∼50%, in purely ocular disease) and are highly specific. If negative, test anti-MuSK and, where available, anti-LRP4.
• Electrodiagnostics: repetitive nerve stimulation at 2–3 Hz shows a decremental drop in compound muscle action potential amplitude of >10% — the electrical signature of failing junctions. Single-fiber EMG is the most sensitive test (>95%), demonstrating increased "jitter" and blocking.
• Bedside pharmacology: the historic edrophonium (Tensilon) test — a short-acting cholinesterase inhibitor that transiently reverses weakness (e.g., lifts a ptotic lid). It has largely been supplanted by the safer ice-pack test and serology.
• Imaging: chest CT or MRI to look for thymoma.

Every new diagnosis should also prompt thyroid testing, since autoimmune thyroid disease coexists in ∼10–15%.

Treatment, crisis, and a vignette

Management works at three levels. Symptomatic: pyridostigmine, an acetylcholinesterase inhibitor, lets released ACh linger in the cleft so it can find the depleted receptors — it eases symptoms but does not treat the autoimmunity. Immunomodulation: corticosteroids and steroid-sparing agents (azathioprine, mycophenolate) reduce antibody production; newer complement inhibitors (eculizumab, ravulizumab) and FcRn blockers (efgartigimod) directly target the pathogenic pathways. Definitive: thymectomy benefits thymoma cases and non-thymomatous AChR-positive patients under ∼65.

The red flag is myasthenic crisis: respiratory failure from diaphragm and intercostal weakness, affecting ∼15–20% of patients at some point and requiring ICU care with plasma exchange or IVIG. Do not wait for a low oxygen saturation — hypoxia is a late sign. Track the forced vital capacity; a falling FVC toward ∼15 mL/kg (or ∼1 L in an adult) signals impending need for intubation. Common triggers include infection, surgery, tapering immunosuppression, and certain drugs (aminoglycosides, fluoroquinolones, magnesium, beta-blockers).

Vignette: a 28-year-old woman notes double vision that clears when she covers one eye and a droopy right lid that is barely noticeable at breakfast but obvious by dinner. Over weeks her voice "tires out" during long phone calls and she chokes on water. Exam shows fatigable ptosis on sustained upgaze; sensation and reflexes are normal. Anti-AChR antibodies are positive, 3 Hz repetitive stimulation shows an 18% decrement, and chest CT reveals a thymoma — a textbook presentation of generalized AChR-positive MG.

Myasthenia gravis vs Lambert-Eaton myasthenic syndrome (LEMS): both cause fatigable weakness but attack opposite sides of the synapse.

Feature	Myasthenia Gravis (MG)	Lambert-Eaton (LEMS)
Target antigen	Postsynaptic ACh receptor (AChR); some MuSK/LRP4	Presynaptic P/Q-type voltage-gated Ca²⁺ channel
Effect of activity	Weakness worsens with repeated effort	Strength briefly improves with initial effort (facilitation)
First muscles hit	Ocular (ptosis, diplopia) → bulbar, limbs	Proximal legs; ocular sparing early
Autonomic signs	Absent	Common — dry mouth, constipation, impotence
Key association	Thymoma / thymic hyperplasia	Small-cell lung cancer (∼50–60%)
Nerve-conduction (repetitive stim)	Decremental response at low frequency (2–3 Hz)	Incremental response after high-freq / exercise